Esreboxetine

Drug Profile

Esreboxetine

Alternative Names: [S,S]-Reboxetine; PNU-165442G

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Morpholines; Urologics
  • Mechanism of Action Adrenergic uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic neuropathies; Fibromyalgia; Major depressive disorder; Postherpetic neuralgia; Stress incontinence

Most Recent Events

  • 12 Mar 2014 Efficacy and adverse events data from a phase II trial in Stress incontinence presented at the 103rd Annual Meeting of the American Urological Association (AUA-2008) ,
  • 25 Feb 2009 Discontinued - Phase-II for Diabetic neuropathies in USA, Czech Republic, Finland, Netherlands, South Africa and Spain (PO)
  • 25 Feb 2009 Discontinued - Phase-II for Major depressive disorder in Estonia and Russia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top